Abstract
In the treatment of polymyositis (PM) and dermatomyositis (DM), muscle inflammation and underlying autoimmunity need to be suppressed promptly; however, catabolic effects of corticosteroids such as myopathy can be detrimental in PM/DM. In this study, we aimed to assess the corticosteroid-sparing effect of tacrolimus in the initial treatment of PM/DM. We retrospectively identified 19 PM/DM patients who received initial treatment with prednisolone at an initial dose of 1 mg/kg/day (Conventional Monotherapy, our standard therapy before 2008) and 23 patients with tacrolimus plus prednisolone at an initial dose 0.8 mg/kg/day (Tacrolimus Combination, our standard therapy after 2008). Data until 36 months after commencing treatment were collected. There were no statistically significant differences in baseline characteristics between two groups. Median daily dose of prednisolone in the Tacrolimus Combination Group was significantly lower than that in the Conventional Monotherapy Group during the study period, whereas the proportion of patients who required additional immunosuppressive medications for remission induction was comparable. Remission was achieved in all patients, except one who died of refractory interstitial lung disease ...Continue Reading
References
Feb 20, 1975·The New England Journal of Medicine·A Bohan, J B Peter
Feb 13, 1975·The New England Journal of Medicine·A Bohan, J B Peter
Feb 1, 1994·The American Journal of Medicine·K G SaagD E Furst
Jun 15, 1996·The Journal of Clinical Investigation·N GoebelsR Hohlfeld
Aug 28, 1998·Bone Marrow Transplantation·P JacobsonV Ratanatharathorn
May 29, 1999·Lancet·C V OddisT E Starzl
Mar 22, 2002·Journal of the American Academy of Dermatology·Richard D Sontheimer
Jan 1, 2003·Rheumatic Diseases Clinics of North America·Marinos C Dalakas
Jul 18, 2003·Rheumatology·D A IsenbergUNKNOWN International Myositis and Clinical Studies Group (IMACS)
Nov 4, 2005·Medicine·Terrance P O'HanlonFrederick W Miller
May 15, 2007·Rheumatology·J Tomasová StudynkováJ Vencovsky
Sep 16, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Andreas E R FasthVivianne Malmström
Feb 5, 2010·Clinical Rheumatology·Masaru AndoToshihide Kumamoto
May 15, 2010·International Journal of Dermatology·Siamak Moghadam-Kia, Victoria P Werth
May 19, 2010·Scandinavian Journal of Rheumatology·Y H LeeG G Song
Mar 9, 2011·Lupus·Y H LeeG G Song
Jul 12, 2011·Autoimmunity Reviews·Isabelle Marie, Luc Mouthon
Apr 4, 2012·Annals of the Rheumatic Diseases·Frederick W Miller
Sep 8, 2012·Current Opinion in Rheumatology·Rohit Aggarwal, Chester V Oddis
Nov 24, 2012·BMC Musculoskeletal Disorders·Yasuhiro ShimojimaShu-ichi Ikeda
Mar 13, 2013·Rheumatology·Shigeru TanakaHiroshi Nakajima
Apr 11, 2013·PloS One·Yasuhito HamaguchiMasataka Kuwana
Nov 30, 2013·Arthritis Research & Therapy·Isabelle MarieStéphane Dominique
Apr 26, 2014·Rheumatology·Takashi KuritaTatsuya Atsumi
Apr 26, 2014·Hepatology International·Jinyang GuYitao Ding
Citations
Jun 22, 2016·Scientific Reports·Chia-Chun TsengJeng-Hsien Yen
Jul 28, 2016·International Journal of Rheumatic Diseases·Ken-Ichi UenoShu-Ichi Ikeda
Apr 11, 2018·Current Rheumatology Reports·Christopher A Mecoli, Lisa Christopher-Stine
Apr 20, 2018·Modern Rheumatology·Hirokazu Sasaki, Hitoshi Kohsaka
Nov 22, 2017·The Journal of Dermatological Treatment·Verena Isak, Joseph L Jorizzo
Aug 6, 2016·Therapeutic Advances in Musculoskeletal Disease·James LillekerRobert Cooper
Sep 2, 2019·Current Rheumatology Reports·Kristen L ChenVictoria P Werth
Jan 8, 2019·Current Treatment Options in Rheumatology·Simone Barsotti, Ingrid E Lundberg